Thus, CDH17 constitutes a promising therapeutic candidate for preventing metastatic progression in CRC by using either specific monoclonal antibodies against the RGD motif of CDH17 [21], CAR-T cells [22], or an anti-NLV peptide blocking CDH17/DSC1 binding [19]. Here, DSC1 is linked to colorectal carcinoma.